Kiora Pharmaceuticals IncNASDAQ:KPRX
- LAST PRICE3.5682
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.4600/ 7
- Ask / Lots3.6500/ 1
- Open / Previous Close--- / 3.5682
- Day Range---
- 52 Week Range
- Volume3,957
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KPRX |
|---|---|---|
| 11:00 ET | 500 | 3.57 |
| 11:03 ET | 1504 | 3.5 |
| 11:09 ET | 1500 | 3.505 |
| 11:30 ET | 173 | 3.5576 |
| 11:48 ET | 450 | 3.5 |
| 11:50 ET | 189 | 3.51 |
| 11:59 ET | 520 | 3.51 |
| 12:55 ET | 140 | 3.55 |
| 01:02 ET | 300 | 3.549 |
| 01:15 ET | 200 | 3.5641 |
| 01:49 ET | 1883 | 3.57 |
| 01:51 ET | 1000 | 3.59 |
| 02:56 ET | 1000 | 3.57 |
| 03:03 ET | 100 | 3.59 |
| 03:28 ET | 288 | 3.57 |
| 03:30 ET | 232 | 3.56 |
| 03:57 ET | 140 | 3.56 |
| 04:00 ET | 676 | 3.5682 |
Today
Press Release: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesKiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
Oct 29, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiora Pharmaceuticals Inc | 10.6M | -0.5x | --- |
Cingulate Inc | 10.5M | 0.0x | --- |
CERo Therapeutics Holdings Inc | 10.4M | -0.2x | --- |
StimCell Enegetics Inc | 9.9M | -465.4x | --- |
Biora Therapeutics Inc | 11.5M | 0.0x | --- |
NKGen Biotech Inc | 9.7M | -0.1x | --- |
Company Information
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
Contact Information
- Headquarters
- 332 ENCINITAS BOULEVARD, SUITE 102ENCINITAS, CA, United States 92024
- Phone
- 781-788-8869
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Praveen Tyle
- President, Chief Executive Officer, Director
- Brian Strem
- Chief Financial Officer
- Melissa Tosca
- Chief Development Officer
- Eric Daniels
- Director
- Aron Shapiro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.6M |
|---|---|
Revenue (TTM) | $16.0M |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-7.76 |
Book Value | $7.14 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | 3.9x |
Operating Margin | 16.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
